Trial Profile
A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs FF-10101-01 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors FujiFilm Pharmaceuticals USA
- 05 Apr 2022 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Results of a Phase 1 dose escalation trial examining the safety, efficacy, pharmacokinetics, and pharmacodynamics presented at the 26th Congress of the European Haematology Association
- 08 Jun 2021 Results of Phase 1 dose escalation trial (n=52) assessing the safety, efficacy, pharmacokinetics, and pharmacodynamics of FF-10101-01 in patients with relapsed/refractory primary or secondary acute myeloid leukemia, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.